AbbVie Work in process increased by 7.8% to $2.28B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 9.9%, from $2.07B to $2.28B. Over 4 years (FY 2020 to FY 2024), Work in process shows an upward trend with a 12.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.37B | $1.33B | $1.19B | $1.24B | $1.25B | $1.31B | $1.42B | $1.31B | $1.61B | $1.69B | $1.64B | $1.89B | $1.93B | $2.07B | $1.95B | $1.97B | $2.11B | $2.28B |
| QoQ Change | — | -3.2% | -10.2% | +3.5% | +1.2% | +4.7% | +8.3% | -7.4% | +22.4% | +5.2% | -2.8% | +15.0% | +2.1% | +7.3% | -5.8% | +1.2% | +7.0% | +7.8% |
| YoY Change | — | — | — | — | -8.9% | -1.4% | +18.8% | +6.2% | +28.5% | +29.1% | +15.9% | +44.1% | +20.2% | +22.5% | +18.7% | +4.4% | +9.5% | +9.9% |
| % of Inventories | 40.5% | 42.9% | 38.1% | 35.5% | 36.8% | 41.3% | 39.6% | 34.2% | 39.6% | 42.5% | 40.1% | 44.5% | 45.8% | 46.5% | 46.7% | 43.6% | 42.6% | 46.1% |
| Share Change | — | +2.4pp | -4.8pp | -2.7pp | +1.4pp | +4.5pp | -1.7pp | -5.4pp | +5.4pp | +2.8pp | -2.4pp | +4.4pp | +1.2pp | +0.8pp | +0.1pp | -3.0pp | -1.0pp | +3.5pp |
We use cookies for analytics. See our Privacy and Cookie Policy.